Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
106 hedge funds and large institutions have $475M invested in Syros Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 12 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 29
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
5% more funds holding
Funds holding: 101 → 106 (+5)
19% less capital invested
Capital invested by funds: $590M → $475M (-$115M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
58% less call options, than puts
Call options by funds: $1.32M | Put options by funds: $3.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.35M |
| 3 |
BlackRock
New York
|
+$8.75M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$8.15M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$13.8M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$4.14M |
| 3 |
Millennium Management
New York
|
-$2.2M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.04M |
| 5 |
CIA
Capital Impact Advisors
Boston,
Massachusetts
|
-$1.83M |
SYRS Hedge Fund Activity: Q1 2021 in Review
106 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2021, worth a combined $475M — down 19% from $590M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new SYRS positions and 12 closed out — a net gain of 5 holders — while 44 added to existing stakes and 29 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $24.7M. The largest seller was ARK Investment Management, cutting an estimated $13.8M.
- 106 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2021, up from 101 in Q4 2020.
- Funds reported $475M of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2021, down 19% quarter-over-quarter.
- 17 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 12 closed out, a net change of +5 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Fidelity Investments, an estimated $24.7M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was ARK Investment Management, an estimated $13.8M sold.
Based on aggregated 13F filings for Q1 2021.